Erectile dysfunction

The Lancet

Volumn 381, Issue 9861, 2013, Pages 153-165

  Shamloul, Rany ^a,b   Ghanem, Hussein ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

MIRODENAFIL; MVIX; SILDENAFIL; TADALAFIL; TESTOSTERONE; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

AGING; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; ELECTROCARDIOGRAM; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HEALTH HAZARD; HUMAN; LABORATORY TEST; LIFESTYLE; LIFESTYLE MODIFICATION; MARITAL THERAPY; MEDICAL DEVICE; MEDICAL HISTORY; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PENIS ERECTION; PENIS PROSTHESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; VACUUM CONSTRICTIVE DEVICE;

EID: 84872087928     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60520-0     Document Type: Review

References (141)

1. National Institutes of Health. Consensus development conference statement. Impotence. December 7-9, 1992. Int J Impot Res 1993; 5: 181-284.
2. Smith GE. Papyrus ebers. English translation. Chicago: Ares Publishers, 1974.
3. Shah J. Erectile dysfunction through the ages. BJU Int 2002; 90: 433-41.
4. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-404.
5. Guay AT, Perez JB, Jacobson J, Newton RA. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 2001; 22: 793-97.
6. Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C. PDE5 inhibitors: in vitro and in vivo pharmacological profile. Curr Pharm Des 2009; 15: 3464-75.
7. Fisher WA, Rosen RC, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study phase II: understanding PDE5 inhibitor treatment seeking patterns, among men with erectile dysfunction. J Sex Med 2004; 1: 150-60.
8. Sairam K, Kulinskaya E, Hanbury D, Boustead G, McNicholas T. Oral sildenafil (Viagra) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital. BMC Urol 2002; 2: 4.
9. Tomlinson J, Wright D. Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. BMJ 2004; 328: 1037.
10. Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007; 19: 253-64.
11. Supuran CT, Mastrolorenzo A, Barbaro G, Scozzafava A. Phosphodiesterase 5 inhibitors-drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr Pharm Des 2006; 12: 3459-65.
12. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005; 96: 257-80.
13. Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/ epidemiology/risk factors for sexual dysfunction. J Sex Med 2010; 7: 1598-607.
14. Bejin A. The epidemiology of premature ejaculation and of its association with erectile dysfunction. Adrologie 1999; 9: 211-25.
15. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-11.
16. Pinnock CB, Stapleton AM, Marshall VR. Erectile dysfunction in the community: a prevalence study. Med J Aust 1999; 171: 353-57.
17. Nicolosi A, Glasser DB, Kim SC, Marumo K, Laumann EO, for the GSSAB Investigators' Group. Sexual behaviour and dysfunction and help-seeking patterns in adults aged 40-80 years in the urban population of Asian countries. BJU Int 2005; 95: 609-14.
18. Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003; 61: 201-06.
19. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163: 460-63.
20. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139: 161-68.
21. Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999; 84: 50-56.
22. Rosen RC, Link CL, O'Leary MP, Giuliano F, Aiyer LP, Mollon P. Lower urinary tract symptoms and sexual health: the role of gender, lifestyle and medical comorbidities. BJU Int 2009; 103 (suppl 3): 42-47.
23. Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84: 108-13.
24. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294: 2996-3002.
25. Quek KF, Sallam AA, Ng CH, Chua CB. Prevalence of sexual problems and its association with social, psychological and physical factors among men in a Malaysian population: a cross-sectional study. J Sex Med 2008; 5: 70-76.
26. Clark NG, Fox KM, Grandy S, for the SHIELD Study Group. Symptoms of diabetes and their association with the risk and presence of diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). Diabetes Care 2007; 30: 2868-73.
27. Ponholzer A, Gutjahr G, Temml C, Madersbacher S. Is erectile dysfunction a predictor of cardiovascular events or stroke? A prospective study using a validated questionnaire. Int J Impot Res 2010; 22: 25-29.
28. Chung SD, Chen YK, Lin HC, Lin HC. Increased risk of stroke among men with erectile dysfunction: a nationwide population-based study. J Sex Med 2011; 8: 240-46.
29. Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58: 1378-85.
30. Cheng JY, Ng EM. Body mass index, physical activity and erectile dysfunction: an U-shaped relationship from population-based study. Int J Obes (Lond) 2007; 31: 1571-78.
31. Rosen RC, Wing R, Schneider S, Gendrano N 3rd. Epidemiology of erectile dysfunction: the role of medical comorbidities and lifestyle factors. Urol Clin North Am 2005; 32: 403-17, v.
32. Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291: 2978-84.
33. Esposito K, Ciotola M, Giugliano F, et al. Effects of intensive lifestyle changes on erectile dysfunction in men. J Sex Med 2009; 6: 243-50.
34. Esposito K, Giugliano D. Lifestyle/dietary recommendations for erectile dysfunction and female sexual dysfunction. Urol Clin North Am 2011; 38: 293-301.
35. Esposito K, Giugliano F, De Sio M, et al. Dietary factors in erectile dysfunction. Int J Impot Res 2006; 18: 370-74.
36. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res 2006; 18: 405-10.
37. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-13.
38. Prieto D. Physiological regulation of penile arteries and veins. Int J Impot Res 2008; 20: 17-29.
39. Carson C, Dean J, Wylie M. Management of erectile dysfunction in clinical practice. New York: Springer Medical Publishing, 2006.
40. Siddiqui MA, Peng B, Shanmugam N, et al. Erectile dysfunction in young surgically treated patients with lumbar spine disease: a prospective follow-up study. Spine (Phila Pa 1976) 2012; 37: 797-801.
41. Mulhall JP. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 2008; 18: 613-20.
42. Traish AM, Munarriz R, O'Connell L, et al. Effects of medical or surgical castration on erectile function in an animal model. J Androl 2003; 24: 381-87.
43. Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011; 165: 687-701.
44. Jackson G. The importance of risk factor reduction in erectile dysfunction. Curr Urol Rep 2007; 8: 463-66.
45. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1: 181-84.
46. Mittawae B, El-Nashaar AR, Fouda A, Magdy M, Shamloul R. Incidence of erectile dysfunction in 800 hypertensive patients: a multicenter Egyptian national study. Urology 2006; 67: 575-78.
47. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188-91.
48. Nehra A, Jackson G, Miner M, et al. The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87: 766-78.
49. Böhm M, Baumhäkel M, Teo K, et al, for the ONTARGET/ TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010; 121: 1439-46.
50. Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the "tip of the iceberg" of a systemic vascular disorder? Eur Urol 2003; 44: 352-54.
51. Wespes E, Schulman C. Venous impotence: pathophysiology, diagnosis and treatment. J Urol 1993; 149: 1238-45.
52. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005; 32: 379-95, v.
53. Aversa A, Rossi F, Francomano D, et al. Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. Int J Impot Res 2008; 20: 566-73.
54. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011; 26: 130-40.
55. Thomas A, Woodard C, Rovner ES, Wein AJ. Urologic complications of nonurologic medications. Urol Clin North Am 2003; 30: 123-31.
56. Do C, Huyghe E, Lapeyre-Mestre M, Montastruc JL, Bagheri H. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Drug Saf 2009; 32: 591-97.
57. Baumhäkel M, Schlimmer N, Kratz M, Hackett G, Jackson G, Böhm M. Cardiovascular risk, drugs and erectile function- a systematic analysis. Int J Clin Pract 2011; 65: 289-98.
58. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569-74, discussion 574-75.
59. El-Sakka AI. Association of risk factors and medical comorbidities with male sexual dysfunctions. J Sex Med 2007; 4: 1691-700.
60. Ponholzer A, Temml C, Mock K, Marszalek M, Obermayr R, Madersbacher S. Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 2005; 47: 80-85, discussion 85-86.
61. Gatti A, Mandosi E, Fallarino M, et al. Metabolic syndrome and erectile dysfunction among obese non-diabetic subjects. J Endocrinol Invest 2009; 32: 542-45.
62. Demir O, Akgul K, Akar Z, et al. Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome. Aging Male 2009; 12: 29-34.
63. Hirshkowitz M, Karacan I, Arcasoy MO, Acik G, Narter EM, Williams RL. Prevalence of sleep apnea in men with erectile dysfunction. Urology 1990; 36: 232-34.
64. Holden CA, McLachlan RI, Pitts M, et al. Determinants of male reproductive health disorders: the Men in Australia Telephone Survey (MATeS). BMC Public Health 2010; 10: 96.
65. Bellinghieri G, Santoro D, Mallamace A, Savica V. Sexual dysfunction in chronic renal failure. J Nephrol 2008; 21 (suppl 13): S113-17.
66. Huyghe E, Kamar N, Wagner F, et al. Erectile dysfunction in end-stage liver disease men. J Sex Med 2009; 6: 1395-401.
67. Köeoǧlu N, Köseoǧlu H, Ceylan E, Cimrin HA, Ozalevli S, Esen A. Erectile dysfunction prevalence and sexual function status in patients with chronic obstructive pulmonary disease. J Urol 2005; 174: 249-52, discussion 252.
68. The Process of Care Consensus Panel. The process of care model for evaluation and treatment of erectile dysfunction. Int J Impot Res 1999; 11: 59-70, discussion 70-74.
69. Hatzichristou D, Rosen RC, Derogatis LR, et al. Recommendations for the clinical evaluation of men and women with sexual dysfunction. J Sex Med 2010; 7: 337-48.
70. Eardley I, Donatucci C, Corbin J, et al. Pharmacotherapy for erectile dysfunction. J Sex Med 2010; 7: 524-40.
71. Hatzimouratidis K, Amar E, Eardley I, et al, for the European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57: 804-14.
72. Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010; 7: 3572-88.
73. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-26.
74. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
75. Ghanem H, Shamloul R. An evidence-based perspective to commonly performed erectile dysfunction investigations. J Sex Med 2008; 5: 1582-89.
76. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol 2006; 50: 721-31.
77. Miner MM. Erectile dysfunction: a harbinger or consequence: does its detection lead to a window of curability? J Androl 2011; 32: 125-34.
78. Vardi Y, Dayan L, Apple B, Gruenwald I, Ofer Y, Jacob G. Penile and systemic endothelial function in men with and without erectile dysfunction. Eur Urol 2009; 55: 979-85.
79. Peled N, Shitrit D, Fox BD, et al. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension. J Rheumatol 2009; 36: 970-75.
80. El Melegy NT, Ali ME, Awad EM. Plasma levels of endothelin-1, angiotensin II, nitric oxide and prostaglandin E in the venous and cavernosal blood of patients with erectile dysfunction. BJU Int 2005; 96: 1079-86.
81. Bocchio M, Desideri G, Scarpelli P, et al. Endothelial cell activation in men with erectile dysfunction without cardiovascular risk factors and overt vascular damage. J Urol 2004; 171: 1601-04.
82. Baumhäkel M, Werner N, Böhm M, Nickenig G. Circulating endothelial progenitor cells correlate with erectile function in patients with coronary heart disease. Eur Heart J 2006; 27: 2184-88.
83. Foresta C, Caretta N, Lana A, Cabrelle A, PalG, Ferlin A. Circulating endothelial progenitor cells in subjects with erectile dysfunction. Int J Impot Res 2005; 17: 288-90.
84. Esposito K, Ciotola M, Maiorino MI, et al. Circulating CD34+ KDR+ endothelial progenitor cells correlate with erectile function and endothelial function in overweight men. J Sex Med 2009; 6: 107-14.
85. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302-06.
86. Hannan JL, Maio MT, Komolova M, Adams MA. Beneficial impact of exercise and obesity interventions on erectile function and its risk factors. J Sex Med 2009; 6 (suppl 3): 254-61.
87. Hannan JL, Heaton JP, Adams MA. Recovery of erectile function in aging hypertensive and normotensive rats using exercise and caloric restriction. J Sex Med 2007; 4: 886-97.
88. Mannino DM, Klevens RM, Flanders WD. Cigarette smoking: an independent risk factor for impotence? Am J Epidemiol 1994; 140: 1003-08.
89. Guay AT, Perez JB, Heatley GJ. Cessation of smoking rapidly decreases erectile dysfunction. Endocr Pract 1998; 4: 23-26.
90. Horasanli K, Boylu U, Kendirci M, Miroglu C. Do lifestyle changes work for improving erectile dysfunction? Asian J Androl 2008; 10: 28-35.
91. Chew KK, Bremner A, Stuckey B, Earle C, Jamrozik K. Alcohol consumption and male erectile dysfunction: an unfounded reputation for risk? J Sex Med 2009; 6: 1386-94.
92. Miller NS, Gold MS. The human sexual response and alcohol and drugs. J Subst Abuse Treat 1988; 5: 171-77.
93. Maio G, Saraeb S, Marchiori A. Physical activity and PDE5 inhibitors in the treatment of erectile dysfunction: results of a randomized controlled study. J Sex Med 2010; 7: 2201-08.
94. Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Arch Intern Med 2011; 171: 1797-803.
95. Konstantinos G, Petros P. Phosphodiesterase-5 inhibitors: future perspectives. Curr Pharm Des 2009; 15: 3540-51.
96. Brant WO, Bella AJ, Lue TF. Treatment options for erectile dysfunction. Endocrinol Metab Clin North Am 2007; 36: 465-79.
97. Andersson KE. Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 2011; 63: 811-59.
98. Viagra (sildenafilcitrate) prescribing information. http://www.pfizer. com/files/products/uspi-viagra.pdf (accessed March 1, 2012).
99. Levitra (vardenafilhydrochloride) prescribing information. http://www.levitra.com/assets/pdf/PI.pdf (accessed March 1, 2012).
100. Cialis (tadalafil) prescribing information. http://pi.lilly.com/us/ cialis-pi.pdf (accessed March 1, 2012).
101. Setter SM, Iltz JL, Fincham JE, Campbell RK, Baker DE. Phosphodiesterase 5 inhibitors for erectile dysfunction. Ann Pharmacother 2005; 39: 1286-95.
102. Carson CC 3rd. Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Urol Clin North Am 2007; 34: 507-15, vi.
103. Kendirci M, Tanriverdi O, Trost L, Hellstrom WJ. Management of sildenafil treatment failures. Curr Opin Urol 2006; 16: 449-59.
104. Behr-Roussel D, Gorny D, Mevel K, et al. Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 2005; 47: 87-91.
105. Ferrini MG, Kovanecz I, Sanchez S, et al. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis in the rat. Biol Reprod 2007; 76: 915-23.
106. McMahon CG. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol 2006; 50: 215-17.
107. Porst H, Giuliano F, Glina S, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351-59.
108. Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med 2009; 6: 2039-48.
109. Porst H, Rajfer J, CasabA, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008; 5: 2160-69.
110. Bella AJ, Deyoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 2007; 52: 990-1005.
111. Gruenwald I, Leiba R, Vardi Y. Effect of sildenafil on middle-aged sexually active males with no erectile complaints: a randomized placebo-controlled double-blind study. Eur Urol 2009; 55: 969-76.
112. Ekmekçioǧlu O, Inci M, Demirci D, Tatlişen A. Effects of sildenafil citrate on ejaculation latency, detumescence time, and refractory period: placebo-controlled, double-blind, crossover laboratory setting study. Urology 2005; 65: 347-52.
113. Morganroth J, Ilson BE, Shaddinger BC, et al. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004; 93: 1378-83, A6.
114. Aoyagi T, Hayakawa K, Miyaji K, Ishikawa H, Hata M. Sildenafil induced priapism. Bull Tokyo Dent Coll 1999; 40: 215-17.
115. King SH, Hallock M, Strote J, Wessells H. Tadalafil-associated priapism. Urology 2005; 66: 432.
116. Tomsak R. PDE5 inhibitors and permanent visual loss. Int J Impot Res 2005; 17: 547-49.
117. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002; 60 (suppl 2): 12-27.
118. McGwin G Jr. Phosphodiesterase type 5 inhibitor use and hearing impairment. Arch Otolaryngol Head Neck Surg 2010; 136: 488-92.
119. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000; 164: 371-75.
120. Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2008; 179 (suppl): S97-102.
121. Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med 2005; 2: 559-64.
122. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005; 65: 1621-50.
123. Perimenis P, Konstantinopoulos A, Perimeni PP, et al. Long-term treatment with intracavernosal injections in diabetic men with erectile dysfunction. Asian J Androl 2006; 8: 21924.
124. Williams G, Abbou CC, Amar ET, et al, for the MUSE Study Group. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br J Urol 1998; 81: 889-94.
125. Glina S, Porst H. Vacuum erection devices. In: Porst H, Buvat J, eds. Standard practice in sexual medicine. Malden, MA: Blackwell/ISSM, 2006: 121-25.
126. Wessels H. Vacuum erection devices. In: Mulcahy J, ed. Male sexual function, a guide to clinical management. Totowa, NJ: Humana Press, 2006: 323-29.
127. Bettocchi C, Palumbo F, Spilotros M, et al. Patient and partner satisfaction after AMS inflatable penile prosthesis implant. J Sex Med 2010; 7: 304-09.
128. Selph JP, Carson CC 3rd. Penile prosthesis infection: approaches to prevention and treatment. Urol Clin North Am 2011; 38: 227-35.
129. Brioni JD, Nakane M, Hsieh GC, Moreland RB, Kolasa T, Sullivan JP. Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002; 14: 8-14.
130. Venkateswarlu K, Giraldi A, Zhao W, et al. Potassium channels and human corporeal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J Urol 2002; 168: 355-61.
131. Chitaley K, Wingard CJ, Clinton Webb R, et al. Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001; 7: 119-22.
132. Martin WJ, McGowan E, Cashen DE, et al. Activation of melanocortin MC(4) receptors increases erectile activity in rats ex copula. Eur J Pharmacol 2002; 454: 71-79.
133. Rogers JH, Karimi H, Kao J, et al. Internal pudendal artery stenoses and erectile dysfunction: correlation with angiographic coronary artery disease. Catheter Cardiovasc Interv 2010; 76: 882-87.
134. Chung E, Brock GB. Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction. Curr Urol Rep 2011; 12: 432-43.
135. Babaev A, Jhaveri RR. Angiography and endovascular revascularization of pudendal artery atherosclerotic disease in patients with medically refractory erectile dysfunction. J Invasive Cardiol 2012; 24: 236-40.
136. Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol 2012; 187: 1769-75.
137. Burnett AL. Erectile dysfunction management for the future. J Androl 2009; 30: 391-96.
138. Burchardt M, Burchardt T, Anastasiadis AG, et al. Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. Urology 2005; 66: 665-70.
139. Melman A, Bar-Chama N, McCullough A, Davies K, Christ G. hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 2006; 17: 1165-76.
140. Xie D, Annex BH, Donatucci CF. Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction. Asian J Androl 2008; 10: 23-27.
141. Bivalacqua TJ, Deng W, Kendirci M, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol 2007; 292: H1278-90.